ReposiTrak, Inc. (TRAK) Earnings

Management highlights

- Strategic Framework and Capital Allocation • Maintains a consistent, disciplined strategy focused on building a scalable SaaS platform with recurring revenue, expanding operating margins, strong cash flow generation, and a conservatively capitalized balance sheet • Balances reinvestment for growth and direct shareholder returns; since FY2020, converted over $7 million in one-time legacy revenue to recurring SaaS revenue, growing recurring revenue share from 62% to 98% of total revenue while eliminating $2 million in low-margin, high-touch non-strategic revenue • Since FY2020, reduced annual operating expenses from ~$19 million to ~$16 million, eliminated $6.4 million in bank debt, expanded net margins from ~8% to over 30%, and grew net cash (cash less debt and lease obligations) at a 16% annual compound rate to ~$28 million by FY2025 • Returned ~$5 million to shareholders YTD in FY2026 via common share repurchases, preferred share redemptions, and dividends; has increased the common dividend by 10% three times since launching the program in 2022; repurchased shares are immediately retired for long-term accretion, with $6 million remaining under the current board buyback authorization • Invested in SPAR Group to extend platform capabilities from supply chain intelligence to in-store operational execution, aligned with long-term expansion objectives - Product and Strategic Initiatives • Touchless traceability: An AI-powered, automated FDA-compliant traceability solution for the global food supply chain that requires no manual scanning of products, using electronic data to track items at scale without altering customer distribution center operations; two large U.S. grocery/wholesale customers have already achieved full end-to-end touchless traceability using the solution, and commercial sales have commenced following patent filing • Data error correction: Developed an AI-powered patent-pending system that automatically identifies and corrects incorrect supplier data (a pervasive industry problem with a 50-70% error rate in initial supplier data that cannot be detected by basic manual or automated tools), a unique capability no other competitor offers • SPAR Group collaboration: Partners with SPAR to add in-store execution capabilities to RepositTrack's diagnostic issue identification, closing the gap between detecting problems (such as out-of-stocks, recalled products, or expired merchandise) and resolving them via SPAR's trained field teams; the partnership creates end-to-end diagnosis and remediation for customers, benefiting both retailers and vendors - Technology and Competitive Positioning • Filed two new patent applications during the quarter, one for touchless traceability and one for automated data integrity error correction, expanding the company's U.S. patent portfolio to 9 patents to strengthen competitive moats • Operates from a single unified source code base, enabling faster, lower-cost development with fewer bugs and higher security compared to competitors with multiple disjointed codebases; all customer functionalities share centralized, consistent supplier data, eliminating reconciliation work for customers • Positions the company's end-to-end platform and on-the-ground execution capabilities as a strong defense against competition from AI-generated single-function apps, which lack platform-wide integration, have major security vulnerabilities, and cannot deliver physical in-store remediation - Intellectual Property and Infrastructure • Continues modernizing software architecture and internal systems, including targeted AI initiatives to improve automation, workflow efficiency, and platform scalability, with no expected meaningful increase in operating expenses or capital expenditures for these projects

Guidance

- Management confirmed an expected effective tax rate of approximately 20% going forward, after an 18% effective rate in Q3 FY2026, as the company no longer benefits from large net operating loss carryforwards to offset taxable income - Management expects growing market interest and new customer inquiries/implementations for touchless traceability as the FDA FSMA 204 compliance deadline approaches, with a recognized lag between customer onboarding work and revenue recognition - Management projects that financial impact from the SPAR Group collaboration will become visible in 6 to 9 months, with initial prospect outreach showing strong early interest in the end-to-end diagnostic and remediation offering - No formal full-year financial guidance was provided, but management reaffirmed its commitment to disciplined execution, sustainable recurring revenue growth, continued profitability expansion, prudent capital allocation, and long-term shareholder value creation

Segment performance

RepositTrack reports 98% of total revenue comes from recurring SaaS revenue as of Q3 FY2026, with no traditional product segment breakdown provided in the transcript. Consolidated Q3 FY2026 total revenue was $5.9 million, flat year-over-year (YoY) compared to $5.9 million in Q3 FY2025. Total operating expenses decreased 12% YoY to $3.6 million from $4.1 million in the prior year quarter. Income from operations increased 24% YoY to $2.3 million from $1.8 million. GAAP net income increased 1% YoY to ~$2 million, while net income attributable to common shareholders increased 4% YoY to ~$2 million. Basic EPS was 11 cents, and diluted EPS was 10 cents. For the first nine months of FY2026 YTD, total revenue increased 5% YoY to $17.7 million from $16.8 million, total operating expenses declined 4% YoY to $11.7 million, income from operations increased 28% YoY to $6 million from $4.6 million, GAAP net income increased 6% YoY to $5.5 million, net income to common shareholders increased 9% YoY to $5.4 million, and YTD diluted EPS increased 9% YoY to $0.28 from $0.26. The company ended Q3 FY2026 with $26.4 million in cash and zero bank debt, and generated $6 million in operating cash flow YTD.

Risks & headwinds

- The FDA extended the FSMA 204 compliance deadline, eliminating the elevated onboarding activity that boosted revenue in Q3 FY2025, creating a temporary timing shift that left Q3 FY2026 revenue flat YoY - High error rates (50% to 70%) in incorrect supplier data create widespread systemic risk across the food supply chain, though the company notes its unique AI system addresses this risk that competitors cannot solve - New AI-generated coding tools and standalone AI applications create potential competitive threats from easily built small software solutions, though management argues these tools lack platform functionality, have major security vulnerabilities, and cannot deliver required on-the-ground execution - The SPAR Group collaboration is in very early stages, and there is uncertainty around the timeline and magnitude of future revenue generation from the partnership - The grocery industry is already highly efficient with tight margins, creating a stall point for large efficiency gains from AI and new technologies

Analyst Q&A

• Q: Thomas Forte of Maxim Group asked for Randy Fields' perspective on agentic commerce, a top topic in recent mega-cap tech earnings calls, and what impact it will have on the food retail category. /

  A: Fields explained that agentic AI will not have a significant impact on food retail, because the industry is already highly efficient and is fundamentally people-intensive. He noted AI can already automate ordering and identify operational issues, but cannot resolve those issues in-store. RepositTrack's partnership with SPAR Group, which provides on-the-ground labor to fix issues AI identifies, addresses the real unmet need in the industry, not more AI-generated insights.

• Q: Forte asked how investors will be able to measure the success of the new SPAR Group partnership, including what key performance indicators to watch. /

  A: Fields noted the partnership is only a month old, so financial KPIs are not yet available, but he expects measurable financial impact to appear 6 to 9 months from the call. He added that the first large prospect the pair presented the offering to (a major global CPG drug company) immediately requested to accelerate the partnership, indicating strong early market demand. Fields said large-scale deals are expected, not small-value contracts, if the offering gains traction.